StockNews.com Initiates Coverage on Biocept (NASDAQ:BIOC)

Stock analysts at StockNews.com began coverage on shares of Biocept (NASDAQ:BIOC – Get Rating) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, Maxim Group lowered Biocept from a “buy” rating to a “hold” rating in a research report on Friday, April 14th.

Biocept Stock Performance

Biocept stock opened at $0.25 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.83 and a debt-to-equity ratio of 0.14. Biocept has a 12 month low of $0.24 and a 12 month high of $1.64. The stock’s 50 day simple moving average is $0.32 and its two-hundred day simple moving average is $0.51. The firm has a market cap of $4.40 million, a PE ratio of -0.12 and a beta of 0.92.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Biocept stock. Renaissance Technologies LLC grew its holdings in shares of Biocept, Inc. (NASDAQ:BIOC – Get Rating) by 27.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 116,400 shares of the medical research company’s stock after purchasing an additional 24,800 shares during the quarter. Renaissance Technologies LLC owned approximately 0.69% of Biocept worth $270,000 at the end of the most recent quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Biocept Company Profile

(Get Rating)

Biocept, Inc is an oncology laboratory service company, which engages in the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company was founded on May 12, 1997 and is headquartered in San Diego, CA.